COVID‐19 vaccines and their underbelly: Are we going the right way?
Abstract Background Historically, a critical aetiological agent of health concern stays till eternity after its discovery, so shall it be with the COVID‐19 outbreak. It has transformed human life to a ‘new normal’ with huge tolls on the social, psychological, intellectual and financial spheres. Aim...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-09-01
|
| Series: | Health Science Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/hsr2.1540 |
| _version_ | 1797672522638950400 |
|---|---|
| author | Bhabani Sankar Satapathy Gurudutta Pattnaik Rudra Narayan Sahoo Sovan Pattanaik Ashish K. Sarangi Venkataramana Kandi Snehasish Mishra Ali A. Rabaan Aroop Mohanty Ranjit Sah Ranjan K. Mohapatra |
| author_facet | Bhabani Sankar Satapathy Gurudutta Pattnaik Rudra Narayan Sahoo Sovan Pattanaik Ashish K. Sarangi Venkataramana Kandi Snehasish Mishra Ali A. Rabaan Aroop Mohanty Ranjit Sah Ranjan K. Mohapatra |
| author_sort | Bhabani Sankar Satapathy |
| collection | DOAJ |
| description | Abstract Background Historically, a critical aetiological agent of health concern stays till eternity after its discovery, so shall it be with the COVID‐19 outbreak. It has transformed human life to a ‘new normal’ with huge tolls on the social, psychological, intellectual and financial spheres. Aim This perspective aimed to collate numerous reported COVID‐19 vaccine‐associated adverse events and the predisposing factors. It focussed on the efficacy of mix‐n‐match (cocktail) vaccines to effectively counter COVID‐19 infection to facilitate future research and possible interventions. Material and Methods Databases like Scopus, Pubmed and the Web‐of‐science were searched for published literature on ‘adverse events associated with COVID‐19 vaccine’. The reports and updates from health agencies like the WHO and CDC were also considered for the purpose. The details with respect to the adverse events associated with COVID‐19 vaccination and the predisposing factors were compiled to obtain insights and suggest possible future directions in vaccine research. Results India stood strong to manage its health resources in time and turned into a dominant global vaccine supplier at a time when healthcare infrastructure of many countries was still significantly challenged. Developing indigenous vaccines and the vaccination drive in India were its major achievements during the second and the subsequent COVID‐19 waves. The fully indigenous Covaxin vaccine, primarily as an emergency intervention, was successfully rapidly launched. Similar such vaccines for emergency use were developed elsewhere as well. However, all of these reached the marketplace with a ‘emergency use only’ tag, without formal clinical trials and other associated formalities to validate and verify them as these would require much longer incubation time before they are available for human use. Discussion Many adverse events associated with either the first or the second/booster vaccination doses were reported. Evidently, these associated adverse events were considered as ‘usually rare’ or were often underreported. Without the additional financial or ethical burden on the vaccine companies, fortunately, the Phase IV (human) clinical trials of their manufactured vaccines are occurring by default as the human population receives these under the tag ‘emergency use’. Thus, focused and collaborative strategies to unveil the molecular mechanisms in vaccine‐related adverse events in a time‐bound manner are suggested. Conclusion Reliable data particularly on the safety of children is lacking as majority of the current over‐the‐counter COVID‐19 vaccines were for emergency use. Many of these were still in their Phase III and Phase IV trials. The need for a mutant‐proof, next‐gen COVID‐19 vaccine in the face of vaccine‐associated adverse events is opined. |
| first_indexed | 2024-03-11T21:31:18Z |
| format | Article |
| id | doaj.art-e2587437e6224d1fb4ef2b78d28b5c6a |
| institution | Directory Open Access Journal |
| issn | 2398-8835 |
| language | English |
| last_indexed | 2024-03-11T21:31:18Z |
| publishDate | 2023-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Health Science Reports |
| spelling | doaj.art-e2587437e6224d1fb4ef2b78d28b5c6a2023-09-27T09:16:35ZengWileyHealth Science Reports2398-88352023-09-0169n/an/a10.1002/hsr2.1540COVID‐19 vaccines and their underbelly: Are we going the right way?Bhabani Sankar Satapathy0Gurudutta Pattnaik1Rudra Narayan Sahoo2Sovan Pattanaik3Ashish K. Sarangi4Venkataramana Kandi5Snehasish Mishra6Ali A. Rabaan7Aroop Mohanty8Ranjit Sah9Ranjan K. Mohapatra10School of Pharmaceutical Sciences Siksha O Anusandhan Deemed to be University Bhubaneswar Odisha IndiaSchool of Pharmaceutical Sciences Centurion University of Technology and Management Alluri Nagar Odisha IndiaSchool of Pharmaceutical Sciences Siksha O Anusandhan Deemed to be University Bhubaneswar Odisha IndiaSchool of Pharmaceutical Sciences Siksha O Anusandhan Deemed to be University Bhubaneswar Odisha IndiaDepartment of Chemistry Centurion University of Technology and Management Alluri Nagar Odisha IndiaDepartment of Microbiology Prathima Institute of Medical Sciences Karimnagar Telangana IndiaSchool of Biotechnology Campus‐11, KIIT Deemed‐to‐be‐University Bhubaneswar Odisha IndiaMolecular Diagnostic Laboratory Johns Hopkins Aramco Healthcare Dhahran Saudi ArabiaDepartment of Clinical Microbiology All India Institute of Medical Sciences Gorakhpur Uttar Pradesh IndiaDepartment of Microbiology Tribhuvan University Teaching Hospital Kathmandu NepalDepartment of Chemistry Government College of Engineering Keonjhar Odisha IndiaAbstract Background Historically, a critical aetiological agent of health concern stays till eternity after its discovery, so shall it be with the COVID‐19 outbreak. It has transformed human life to a ‘new normal’ with huge tolls on the social, psychological, intellectual and financial spheres. Aim This perspective aimed to collate numerous reported COVID‐19 vaccine‐associated adverse events and the predisposing factors. It focussed on the efficacy of mix‐n‐match (cocktail) vaccines to effectively counter COVID‐19 infection to facilitate future research and possible interventions. Material and Methods Databases like Scopus, Pubmed and the Web‐of‐science were searched for published literature on ‘adverse events associated with COVID‐19 vaccine’. The reports and updates from health agencies like the WHO and CDC were also considered for the purpose. The details with respect to the adverse events associated with COVID‐19 vaccination and the predisposing factors were compiled to obtain insights and suggest possible future directions in vaccine research. Results India stood strong to manage its health resources in time and turned into a dominant global vaccine supplier at a time when healthcare infrastructure of many countries was still significantly challenged. Developing indigenous vaccines and the vaccination drive in India were its major achievements during the second and the subsequent COVID‐19 waves. The fully indigenous Covaxin vaccine, primarily as an emergency intervention, was successfully rapidly launched. Similar such vaccines for emergency use were developed elsewhere as well. However, all of these reached the marketplace with a ‘emergency use only’ tag, without formal clinical trials and other associated formalities to validate and verify them as these would require much longer incubation time before they are available for human use. Discussion Many adverse events associated with either the first or the second/booster vaccination doses were reported. Evidently, these associated adverse events were considered as ‘usually rare’ or were often underreported. Without the additional financial or ethical burden on the vaccine companies, fortunately, the Phase IV (human) clinical trials of their manufactured vaccines are occurring by default as the human population receives these under the tag ‘emergency use’. Thus, focused and collaborative strategies to unveil the molecular mechanisms in vaccine‐related adverse events in a time‐bound manner are suggested. Conclusion Reliable data particularly on the safety of children is lacking as majority of the current over‐the‐counter COVID‐19 vaccines were for emergency use. Many of these were still in their Phase III and Phase IV trials. The need for a mutant‐proof, next‐gen COVID‐19 vaccine in the face of vaccine‐associated adverse events is opined.https://doi.org/10.1002/hsr2.1540COVID‐19 pandemicCOVID‐19 vaccineefficacy and safetyvaccine‐associated adverse events |
| spellingShingle | Bhabani Sankar Satapathy Gurudutta Pattnaik Rudra Narayan Sahoo Sovan Pattanaik Ashish K. Sarangi Venkataramana Kandi Snehasish Mishra Ali A. Rabaan Aroop Mohanty Ranjit Sah Ranjan K. Mohapatra COVID‐19 vaccines and their underbelly: Are we going the right way? Health Science Reports COVID‐19 pandemic COVID‐19 vaccine efficacy and safety vaccine‐associated adverse events |
| title | COVID‐19 vaccines and their underbelly: Are we going the right way? |
| title_full | COVID‐19 vaccines and their underbelly: Are we going the right way? |
| title_fullStr | COVID‐19 vaccines and their underbelly: Are we going the right way? |
| title_full_unstemmed | COVID‐19 vaccines and their underbelly: Are we going the right way? |
| title_short | COVID‐19 vaccines and their underbelly: Are we going the right way? |
| title_sort | covid 19 vaccines and their underbelly are we going the right way |
| topic | COVID‐19 pandemic COVID‐19 vaccine efficacy and safety vaccine‐associated adverse events |
| url | https://doi.org/10.1002/hsr2.1540 |
| work_keys_str_mv | AT bhabanisankarsatapathy covid19vaccinesandtheirunderbellyarewegoingtherightway AT guruduttapattnaik covid19vaccinesandtheirunderbellyarewegoingtherightway AT rudranarayansahoo covid19vaccinesandtheirunderbellyarewegoingtherightway AT sovanpattanaik covid19vaccinesandtheirunderbellyarewegoingtherightway AT ashishksarangi covid19vaccinesandtheirunderbellyarewegoingtherightway AT venkataramanakandi covid19vaccinesandtheirunderbellyarewegoingtherightway AT snehasishmishra covid19vaccinesandtheirunderbellyarewegoingtherightway AT aliarabaan covid19vaccinesandtheirunderbellyarewegoingtherightway AT aroopmohanty covid19vaccinesandtheirunderbellyarewegoingtherightway AT ranjitsah covid19vaccinesandtheirunderbellyarewegoingtherightway AT ranjankmohapatra covid19vaccinesandtheirunderbellyarewegoingtherightway |